StockNews.com Initiates Coverage on Bio-Path (NASDAQ:BPTH)

Analysts at StockNews.com assumed coverage on shares of Bio-Path (NASDAQ:BPTH) in a research note issued on Thursday. The firm set a “sell” rating on the stock.

Separately, Roth Mkm reaffirmed a “buy” rating and set a $40.00 target price on shares of Bio-Path in a research note on Thursday, April 18th.

Bio-Path Price Performance

Shares of BPTH stock opened at $2.76 on Thursday. The company has a market cap of $1.88 million, a price-to-earnings ratio of -0.07 and a beta of 0.35. The stock has a 50 day simple moving average of $4.54 and a 200-day simple moving average of $8.24. Bio-Path has a 1-year low of $2.35 and a 1-year high of $44.80.

Bio-Path (NASDAQ:BPTH) last announced its earnings results on Friday, March 8th. The company reported ($5.40) earnings per share for the quarter, hitting the consensus estimate of ($5.40). During the same period last year, the company earned ($10.60) EPS. Analysts anticipate that Bio-Path will post -18.71 earnings per share for the current fiscal year.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.